JP Morgan Chase’s Co-Diagnostics CODX Stock Holding History
Bought
Maintained
Sold
Other funds holding CODX
PAG
SAM
SS
HWA
DB
NA
JP Morgan Chase's CODX Position: Q1 2026 in Review
JP Morgan Chase increased its Co-Diagnostics (CODX) stake by 127% in Q1 2026, buying an estimated $96 and bringing the position to 50 shares worth $85. The position accounts for ﹤0.01% of the portfolio, ranked #7322.
JP Morgan Chase first reported a position in CODX in Q2 2020 and has held it in 24 quarters since. The position peaked at $1.19M in Q3 2020. 14 funds tracked by Wall St. Rank hold CODX as of Q1 2026.
- JP Morgan Chase held 50 shares of Co-Diagnostics worth $85 as of Q1 2026.
- JP Morgan Chase bought 28 Co-Diagnostics shares in Q1 2026, an estimated $96.
- Co-Diagnostics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7322 holding.
- JP Morgan Chase first reported a position in Co-Diagnostics in Q2 2020 and has held it in 24 quarters since.
- JP Morgan Chase's Co-Diagnostics position peaked at $1.19M in Q3 2020.
- 14 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.